Compounded GLP-1 Ban Explained: what changed, what did not, and what to check next.
The October 2024 GLP-1 compounding change pushed buyers into confusing searches.
By Peptide Doctor editorial team · Updated
The compounded GLP-1 ban changed the cheap-copy route for Ozempic and Mounjaro style demand in Australia. It did not make every online GLP-1 offer equal, and it did not verify any research peptide seller. Use this explainer to separate approved medicine, telehealth supply, and research-only pages before comparing price.
Why this matters
When regulations move, bad sellers use the confusion.
The useful response is to separate medical access, research-only product buying, and payment risk.
Straight answers
Does this update make peptides approved for human use?
No. Regulatory news is not product approval.
What should buyers check next?
Check the provider, payment terms, COA, HPLC, batch ID, dispatch, and support before payment.
What has to be visible before I pay?
Price, batch ID, COA, HPLC result, payment method, dispatch origin, and support. If those are hidden, slow down.
Is Peptide Doctor medical advice?
No. Peptide Doctor is not a clinic, pharmacy, prescriber, or medical service. Medical questions belong with a qualified practitioner.
What should I check about payment?
Read the payment methods and dispute terms available at checkout. Keep the receipt and order number. Protection depends on the provider, transaction and terms; a logo alone is not a guarantee.
Why does the batch number matter?
A COA or HPLC number is useful only when it belongs to the exact batch being sold. Generic certificates are easy to recycle.
Research peptides are not approved by the TGA for human use. Product links are for checking what is visible before payment, not medical advice.